Tag Archives: acromegaly

Novartis’s Signifor® LAR to treat patients with life-threatening hormonal disorder acromegaly receives FDA approval

Acromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels[1] Signifor LAR, a next-generation somatostatin analog, provides a new option for patients with acromegaly with inadequately controlled disease[2] Signifor LAR FDA approval is … Read the full press release

Novartis’ Signifor® (pasireotide) intramuscular injection to treat adult patients with acromegaly approved by the European Commission

Acromegaly is a rare pituitary disorder, which requires normalization of hormonal levels to help prevent the serious consequences of the disease[1],[2],[3],[4] Approval based on two large phase III trials showing superior efficacy of new formulation of Signifor over current SSAs … Read the full press release